The effect of a Prasugrel- vs. a Ticagrelor-based strategy on total ischaemic and bleeding events in patients with acute coronary syndromes. Issue 3 (26th November 2022)

• Record Type: Journal Article
• Authors: Aytekin, Alp; Coughlan, J J; Ndrepepa, Gjin; Cassese, Salvatore; Lahu, Shqipdona; Kufner, Sebastian; Mayer, Katharina; Xhepa, Erion; Gewalt, Senta; Joner, Michael; Hapfelmeier, Alexander; Angiolillo, Dominick J; Menichelli, Maurizio; Richardt, Gert; Neumann, Franz J; Schunkert, Heribert; Kastrati, Adnan
• Is Part Of: European heart journal. Volume 9:Issue 3(2023)
• Page Start: 231
• Page End: 239
• Publication Date: 2022-11-26
• Subjects: Acute coronary syndromes -- Total events analysis -- Methodological analysis -- Anti-thrombotic therapy; Cardiovascular pharmacology -- Periodicals; 615.71
• DOI: 10.1093/ehjcvp/pvac067
• Languages: English
• ISSNs: 2055-6837

Abstract

Abstract: Aims: The effect of a prasugrel vs. a ticagrelor based strategy on total (including both first and recurrent) ischaemic and bleeding events in patients with acute coronary syndromes (ACS) has not been evaluated. The aim of this analysis was to investigate the treatment effect of a prasugrel vs. a ticagrelor based strategy in patients with ACS undergoing an invasive management strategy when both first and recurrent non-fatal ischaemic and bleeding events are taken into account. Methods and results: This is a post-hoc analysis of the ISAR-REACT 5 randomized control trial, including all 4018 patients in the trial. The main clinical endpoints of interest included ischaemic events [myocardial infarction (MI) and stroke] and bleeding events [Bleeding Academic Research Consortium (BARC) type 3 to 5 bleeding]. An additional endpoint of interest was definite/probable stent thrombosis. The effect of the prasugrel vs. ticagrelor based strategies on these endpoints was evaluated on both time-to-first event and total events analyses. Patients in the prasugrel group had a lower risk of MI in comparison to the ticagrelor group on both time-to-first event [hazard ratio (HR) = 0.61; 95% confidence interval 0.44–0.85] and total events [HR = 0.62 (0.45–0.86)] analysis. The risk of BARC type 3 to 5 bleeding was comparable between the prasugrel and ticagrelor groups on both time-to-first event [HR = 0.96 (0.75–1.25)] and total events [HR = 0.99 (0.76–1.31)] analysis. Conclusion: A prasugrel based strategy was associated with a reduction in total MI events in comparison to a ticagrelor based strategy in patients with ACS undergoing invasive assessment. Total BARC type 3 to 5 bleeding events were comparable between the two groups. Given the importance of this topic, future studies to confirm these findings would be welcome. ClinicalTrials.gov identifier: NCT01944800